November 18, 2009
By:Emmanuel Le Poul
Allosteric modulators are an emerging class of orally available small molecule drugs that may have multiple advantages compared to traditional drugs.
 |
October 28, 2009
By:Benjamin Curtis
Google opened up a whole new era of social media when it released Sidewiki - a tool that allows anyone to comment on any Web site. Now pharma has a new battle to fight.
|
October 21, 2009
Industry Audit and Company of The year.
|
 | October 19, 2009
Pharm Exec interviews some of this year's emerging leaders to learn their strategies for success.
|
October 14, 2009
By:Jerome Wilson, Martin Nemansky
Jerome Wilson and Martin Nemansky, explore some of the difficulties of implementing biomarkers during drug development.
|
October 14, 2009
By:Dan Mendelson
As the health care reform debate continues to rage on Capitol Hill, pharma companies should be engaged in intense strategic planning for the future. Putting together a game plan now for the most likely reform scenarios will help companies to stay ahead of the curve.
|
October 14, 2009
By:Matt Wallach
One feature that should be considered when looking for a new software-as-a-service (SaaS) system is multi-tenancy, which is a chief characteristic of a mature cloud computing application. Here?s what to look for.
|
October 7, 2009
By:Wendy Heckelman
Sales forces can achieve compliance and excellence through individual behavioral fine-tuning and company-wide cultural adjustment.
|
September 9, 2009
By:Sarah Houlton
With a weak pound being outpaced by the euro, many hospitals are sending drugs to the Continent for higher profits. What can NHS do to stop this practice?
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
Applying E-Commerce to Support Discovery and Development of Medicines: Key Lessons and Learnings Tuesday, December 15 @ 11:00 a.m. ET
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?